Table 6.
Results of sleep evaluation by actigraphy in the study groups.
| Variable | Baseline | Final (8 Weeks) |
Within-Group p Value |
Between-Group p Value |
|---|---|---|---|---|
| Sleep latency, min | ||||
| Placebo | 3.3 ± 1.0 | 3.4 ± 0.8 | 0.662 | 0.050 |
| Boswellia | 3.2 ± 0.9 | 2.7 ± 1.0 | 0.016 | |
| AvailOm® | 3.5 ± 0.8 | 3.5 ± 0.9 | 0.843 | |
| Boswellia + AvailOm® | 3.4 ± 1.0 | 3.0 ± 0.9 | 0.048 | |
| Sleep efficiency, % | ||||
| Placebo | 91.5 ± 3.6 | 91.6 ± 3.2 | 0.899 | 0.515 |
| Boswellia | 90.9 ± 2.7 | 91.9 ± 2.7 | 0.050 | |
| AvailOm® | 91.7 ± 3.6 | 91.8 ± 3.0 | 0.755 | |
| Boswellia + AvailOm® | 91.4 ± 3.2 | 92.2 ± 3.4 | 0.119 | |
| Total time in bed, min | ||||
| Placebo | 431.7 ± 60.0 | 422.1 ± 61.3 | 0.430 | 0.462 |
| Boswellia | 416.2 ± 63.0 | 427.8 ± 74.0 | 0.353 | |
| AvailOm® | 411.0 ± 56.0 | 405.6 ± 62.2 | 0.653 | |
| Boswellia + AvailOm® | 419.4 ± 65.0 | 431.7 ± 72.6 | 0.318 | |
| Total sleep time, min | ||||
| Placebo | 396.6 ± 59.6 | 390.0 ± 61.9 | 0.563 | 0.817 |
| Boswellia | 394.6 ± 68.7 | 387.2 ± 70.6 | 0.527 | |
| AvailOm® | 399.5 ± 82.7 | 391.1 ± 91.0 | 0.455 | |
| Boswellia + AvailOm® | 389.2 ± 69.2 | 394.4 ± 77.6 | 0.651 | |
| Wakefulness after sleep onset, min | ||||
| Placebo | 33.3 ± 13.1 | 33.6 ± 13.1 | 0.877 | 0.046 |
| Boswellia | 37.2 ± 13.0 | 32.5 ± 10.5 | 0.019 | |
| AvailOm® | 30.4 ± 13.3 | 30.3 ± 11.4 | 0.947 | |
| Boswellia + AvailOm® | 35.0 ± 10.7 | 28.9 ± 12.2 | 0.002 | |
| Number of awakenings | ||||
| Placebo | 13.8 ± 5.7 | 13.9 ± 5.5 | 0.912 | 0.049 |
| Boswellia | 16.2 ± 5.0 | 13.5 ± 5.0 | 0.009 | |
| AvailOm® | 15.0 ± 5.8 | 15.1 ± 5.3 | 0.954 | |
| Boswellia + AvailOm® | 17.0 ± 6.8 | 14.1 ± 6.0 | 0.005 | |
| Awakenings, mean number of min | ||||
| Placebo | 2.4 ± 0.7 | 2.4 ± 0.6 | 0.773 | 0.750 |
| Boswellia | 2.3 ± 0.4 | 2.4 ± 0.5 | 0.448 | |
| AvailOm® | 2.5 ± 0.8 | 2.5 ± 1.0 | 0.572 | |
| Boswellia + AvailOm® | 2.4 ± 0.7 | 2.3 ± 0.7 | 0.591 |
Data as mean ± standard deviation; min: minutes.